Drugs / Relacorilant
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | LIFYORLI (COPACKAGED) | — | 2026-03-25 | fda.gov ↗ |
Trials 25 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT05347979 | May → Jul 2022 | Cushing syndrome, neoplasm | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04795479 | Jan → May 2021 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04373265 | Sep 2020 → Oct 2023 | adrenal cortex carcinoma | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06094738 | Sep → Nov 2020 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06094725 | Jan → Dec 2020 | liver disease, severe congenital | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03674814 | Oct 2018 → Jun 2024 | prostate cancer | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT03540836 | May → Jul 2018 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03512548 | Apr 2018 → Jul 2019 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03457597 | Mar → Apr 2018 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03442621 | Jan → Feb 2018 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06094790 | May → Nov 2017 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03067376 | Aug → Sep 2016 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06094712 | Apr 2016 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03508635 | Sep 2014 → Dec 2015 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02762981 | May 2016 → May 2020 | cancer | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07259317 | Jan 2026 → Sep 2027 expected | pancreatic ductal adenocarcinoma | Corcept Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT06906341 | Apr 2025 → Aug 2026 overdue | endometrial cancer, fallopian tube cancer, ovarian cancer, peritoneal neoplasm | Corcept Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT05726292 | Jan 2025 → Oct 2027 expected | prostate adenocarcinoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT03776812 | Apr 2019 → Mar 2021 | fallopian tube carcinoma, ovarian cancer, primary peritoneal carcinoma | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03604198 | May 2018 → Dec 2026 expected | endogenous Cushing syndrome | Corcept Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02804750 | Jun 2016 → Sep 2018 | endogenous Cushing syndrome | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05257408 | Jun 2022 → Mar 2025 overdue | fallopian tube neoplasm, ovarian neoplasm, peritoneal neoplasm | Corcept Therapeutics | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04308590 | Jul 2020 → Sep 2024 | Cushing syndrome | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT04329949 | Jun 2020 → Aug 2021 | pancreatic ductal adenocarcinoma | Corcept Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT03697109 | Nov 2018 → Apr 2024 | Cushing syndrome | Corcept Therapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Relacorilant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03697109 ↗ |
| Known as | CORT125134 | “relacorilant (CORT125134)” NCT03604198 ↗ |
| Action | Inhibit | “a novel glucocorticoid receptor (GR) antagonist” NCT02762981 ↗1“Glucocorticoid receptor antagonist” CHEMBL4068611 ↗ |
| Modality | Small molecule | “Relacorilant is a small molecule antagonist of the glucocorticoid receptor (GR).” NCT03776812 ↗ |
| Route | Oral | “oral relacorilant lead-in once-daily” NCT02762981 ↗ |
| Target | NR3C1 | “Glucocorticoid receptor antagonist” CHEMBL4068611 ↗ |